Welcome to our dedicated page for Lensar news (Ticker: LNSR), a resource for investors and traders seeking the latest updates and insights on Lensar stock.
Lensar Inc (LNSR) delivers innovative femtosecond laser systems transforming refractive cataract surgery through proprietary augmented reality imaging. This comprehensive news hub provides investors and medical professionals with essential updates on the company’s technological advancements, financial performance, and market developments.
Access real-time announcements including quarterly earnings reports, product launch details, regulatory milestones, and strategic partnerships. Our curated collection ensures you stay informed about LNSR’s progress in commercializing its precision surgical platforms and expanding its global footprint in ophthalmic care.
Key updates cover FDA clearances, clinical study results, system installations, and executive leadership changes. All content is verified through primary sources to maintain accuracy and compliance with financial disclosure standards.
Bookmark this page for centralized access to Lensar’s official communications and third-party analyses. Monitor the company’s trajectory in advancing cataract surgery technology while maintaining awareness of industry trends affecting medical device innovation.
LENSAR announced the granting of stock options to two newly-hired non-executive employees as employment inducements. The grants, approved by independent board members, total 650 shares with an exercise price of $5.38 per share, matching the closing price on November 1, 2024. The options vest 25% after one year, followed by 36 monthly installments, contingent on continued employment. The 10-year term options are governed by LENSAR's 2024 Employment Inducement Incentive Award Plan.
LENSAR (Nasdaq: LNSR), a global medical technology company specializing in robotic laser solutions for cataract treatment, has announced it will release its third quarter 2024 financial results before market open on Thursday, November 7, 2024. The company will host a conference call and webcast at 8:30 am ET on the same day to discuss financial results and recent corporate highlights. Participants can join via telephone or access the live webcast through LENSAR's website investor section.
LENSAR, Inc. (Nasdaq: LNSR), a global medical technology company specializing in advanced robotic laser solutions for cataract treatment, has announced a significant milestone: over one million procedures have been performed using its technology. Nick Curtis, President and CEO of LENSAR, emphasized the company's commitment to providing innovative robotic laser solutions that enhance clinical efficiencies and outcomes while revolutionizing the patient and surgical experience.
LENSAR introduced its cataract laser LLS platform in 2012 and has since developed the ALLY System, designed for robotic, laser cataract surgery. The ALLY System uniquely combines robotic intelligence and precision with surgeon expertise to deliver advanced cataract procedures aimed at consistently improving clinical outcomes and patient experiences. LENSAR remains the only company focused on robotic laser cataract surgery and plans to continue optimizing premium laser cataract surgery to bring greater value to surgeons, their staff, and patients.
LENSAR, Inc. (Nasdaq: LNSR) has announced the granting of stock options to two newly-hired non-executive employees as inducement awards. These options, approved by a majority of independent board members, allow the purchase of a total of 875 shares of the Company's common stock. The grants, made on October 1, 2024, comply with Nasdaq Listing Rule 5635(c)(4).
Key details of the stock options include:
- Exercise price: $4.40 per share (equal to the closing price on the grant date)
- Vesting schedule: 25% after one year, followed by 36 monthly installments
- Term: 10 years
- Subject to LENSAR's 2024 Employment Inducement Incentive Award Plan
LENSAR (Nasdaq: LNSR) has announced the granting of stock options to three newly-hired non-executive employees as inducement awards. The options, totaling 2,425 shares of the Company's common stock, were granted on September 3, 2024, with an exercise price of $4.63 per share, matching the closing price on the grant date. These options vest over four years, with 25% vesting after one year and the remainder in 36 monthly installments, subject to continued employment. The options have a 10-year term and are governed by LENSAR's 2024 Employment Inducement Incentive Award Plan.
LENSAR (Nasdaq: LNSR), a global medical technology company specializing in advanced laser solutions for cataract treatment, has announced its participation in two upcoming investor conferences. The company will be part of the H.C. Wainwright 26th Annual Global Investment Conference, offering an on-demand presentation available from September 9, 2024, at 7:00 a.m. Eastern Time. Additionally, LENSAR management will attend the Lake Street Capital Markets 8th Annual Best Ideas Growth Conference on September 12, 2024, in New York, where they will conduct one-on-one meetings with institutional investors.
Investors can access the H.C. Wainwright presentation through the Investors section of LENSAR's website at https://ir.lensar.com. These conferences provide LENSAR with opportunities to showcase its innovative cataract treatment technologies and engage with potential investors.
LENSAR (NASDAQ: LNSR) reported strong Q2 2024 results, with total revenue of $12.6 million, up 5% year-over-year. Highlights include:
- Record 17 new ALLY® System placements, highest since launch
- Worldwide procedure volume increased 19% over Q2 2023
- Installed system base grew 16% year-over-year
- Received CE Mark approval for ALLY System
- 79% of revenue from recurring sources
Despite growth, LENSAR reported a net loss of $9.0 million ($0.79 per share). The company ended Q2 with $15.4 million in cash and investments. LENSAR's CEO Nick Curtis expressed optimism about continued growth and market share expansion.
LENSAR (Nasdaq: LNSR) has announced that its ALLY Adaptive Cataract Treatment System has received certification under the EU's Medical Device Regulation. This certification allows LENSAR to introduce ALLY to European surgeons, offering advanced laser technology for cataract procedures. ALLY is the first platform enabling seamless laser cataract procedures in a single, sterile environment.
Key features of ALLY include:
- Enhanced speed and ergonomic design for improved efficiency
- Artificial intelligence for iris registration and astigmatism management
- Automatic cataract density determination and optimization of fragmentation patterns
LENSAR (Nasdaq: LNSR) has granted stock options to three newly-hired non-executive employees as inducement awards. The options, totaling 1,925 shares of common stock, were approved by a majority of independent board members and issued on August 1, 2024. With an exercise price of $5.20 per share, matching the closing price on the grant date, these options have a 10-year term and a vesting schedule of 25% after one year, followed by 36 monthly installments. The grants, made under LENSAR's 2024 Employment Inducement Incentive Award Plan, comply with Nasdaq Listing Rule 5635(c)(4) and aim to attract new talent to the company.
LENSAR, Inc. (Nasdaq: LNSR), a global medical technology company specializing in advanced laser solutions for cataract treatment, has announced the release of its second quarter 2024 financial results. The results will be made public before the market opens on Thursday, August 8, 2024. Following this, LENSAR's management team will host a conference call and webcast at 8:30 am ET on the same day to discuss the financial outcomes and recent company highlights.
Interested parties can join the call by dialing (800) 274 8461 (Domestic) or (203) 518 9848 (International) using the conference ID: LENSAR. A live webcast will also be available in the Investors section of LENSAR's website at www.lensar.com. An archived version of the call will be accessible on the website after the live event.
FAQ
What is the current stock price of Lensar (LNSR)?
What is the market cap of Lensar (LNSR)?
